THE PURPOSE of this report is to present certain preliminary observations on the effects of paraaminobenzoic acid in dermatomyositis and in scleroderma. Neither the cause nor the pathogenesis of these rare conditions is understood. The concept of "diffuse collagen disease," however, is generally accepted as being applicable to them and to lupus erythematosus. Baehr and Pollack1 have pointed out that this does not necessarily indicate a close relationship between these disorders, and that it cannot be assumed that their pathogeneses are similar. Nevertheless, it appeared logical to anticipate from the results obtained in lupus erythematosus2 that paraaminobenzoic acid might also be beneficial in dermatomyositis and in scleroderma.
The rationale for administering large doses of paraaminobenzoic acid to patients with lupus erythematosus has been dealt with elsewhere.2a,c Briefly, it was recalled that exposure to sunlight may induce a relapse or cause an exacerbation of lupus erythematosus. It was
ZARAFONETIS CJD, CURTIS AC, GULICK AE. USE OF PARAAMINOBENZOIC ACID IN DERMATOMYOSITIS AND SCLERODERMA: Report of Six Cases. Arch Intern Med (Chic). 1950;85(1):27–43. doi:10.1001/archinte.1950.00230070049003
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: